Merck is acquiring a startup spun out of Yale called Modifi Bio, which has developed a suite of molecules against ...

Roche’s competition in the eye disease space is intensifying with Renegeron’s high-dose Eylea and looming biosimilar ...

The eye drop maker Ocuphire Pharma and startup Opus Genetics are merging in an all-stock deal, the companies told Endpoints ...

Amgen is moving forward with the launch of Pavblu, its biosimilar to Regeneron's blockbuster Eylea, following an appeals ...

A US drug pricing watchdog has raised the range by which it thinks Pfizer’s heart muscle disease drug tafamidis, marketed as ...

Four senators want to know more about Pfizer and Eli Lilly’s partnerships with telehealth providers, and whether that may ...

A panel of DC-focused lawyers predicted that the anti-China Biosecure Act is likely headed for final passage during the ...

Starboard Value, the activist investor pushing for changes at Pfizer, unveiled its goals for another healthcare company — ...

Be Bio's $82 million round announced Tuesday will help the Cambridge, MA-based biotech fund work for two of its drugs in ...

Samsung Biologics has so far secured at least five major contracts this year, and its latest with an unnamed Asia-based ...

APRIL antibody has passed a registrational test in a rare kidney disease, marking a significant win from its 2018 buyout of ...

In its quest to stay at the top of the obesity drug market, Eli Lilly is following in Novo Nordisk's footsteps by pursuing a ...